Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice.

Abstract excerpt

Patients with GNE myopathy, a progressive and debilitating disease caused by a genetic defect in sialic acid biosynthesis, rely on supportive care and eventually become wheelchair-bound. To elucidate whether GNE myopathy is treatable at a progressive stage of the disease, we examined the efficacy of sialic acid supplementation on symptomatic old GNE myopathy mice that have ongoing, active muscle degeneration. We...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Amyloid beta-Peptides
• Share to Creatine Kinase